The FDA notified the American public of the potential cancer risk associated with Zantac in the days following Valisure's initial discovery of it in 2019. The agency did not immediately issue a recall because of a lack of proper research but directed companies to stop selling the drug in October of the same year. The FDA eventually called a halt on the production of ranitidine products in the US in April 2020, directing consumers of the medication to stop taking it and replace it with an alternative.